The Technical Analyst
IO Biotech, Inc. [IOBT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
IO Biotech, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.67% $1.480
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 97.50 mill |
| EPS: | -1.980 |
| P/E: | -0.750 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 65.88 mill |
| Avg Daily Volume: | 0.137 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.750 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -0.750 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.23 (118.34%) $1.751 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.345 - 1.615 ( +/- 9.12%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Zocca Mai-britt | Buy | 750 000 | Stock Option (Right to Buy) |
| 2024-03-15 | Sullivan Amy | Buy | 280 000 | Stock Option (Right to Buy) |
| 2024-03-15 | Smith Devin Whittemore | Buy | 185 000 | Stock Option (Right to Buy) |
| 2024-03-15 | Burkavage Brian | Buy | 50 000 | Stock Option (Right to Buy) |
| 2024-03-15 | Ahmad Qasim Iftikhar | Buy | 280 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 96.14 |
| Last 87 transactions |
| Buy: 67 695 200 | Sell: 7 604 578 |
Forecast:
16:00 - $1.460
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.460
Forecast 2: 16:00 - $1.460
Forecast 3: 16:00 - $1.460
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.480 (-0.67% ) |
| Volume | 0.0914 mill |
| Avg. Vol. | 0.137 mill |
| % of Avg. Vol | 66.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IOBT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IOBT
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Latest Press Releases
2024-04-15 08:30:00 - Press Release
Io Biotech Expands Senior Leadership Team To Progress Commercialization Readiness
New york, april 15, 2024 (globe newswire) -- io biotech (nasdaq: iobt), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its t-win® platform, today announced that marjan shamsaei, pharmd, joined the company as svp, commercial development and portfolio lead for io102-io103, the company's lead cancer vaccine candidate currently in a pivotal phase 3 trial. ms. shamsaei joins the company's executive team, reporting to io biotech ceo mai-britt zocca, ph.d.
2024-04-09 12:00:00 - Press Release
Io Biotech Presents New Data At Aacr 2024 Further Supporting Dual Mechanism Of Action Of Lead Cancer Vaccine, Io102-io103
New york, april 09, 2024 (globe newswire) -- io biotech (nasdaq: iobt), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its t-win® platform, today shared new data related to the company's lead therapeutic cancer vaccine candidate, io102-io103, at the american association for cancer research (aacr) annual meeting 2024, taking place april 5-10, 2024, in san diego, california. “these data build on earlier studies that demonstrated the mechanism of io102 and io103,” said mai-britt zocca, ph.d.
2024-04-05 08:30:00 - Press Release
Io Biotech Appoints FaiÇal Miyara, Ph.d., As Chief Business Officer
New york, april 05, 2024 (globe newswire) -- io biotech (nasdaq: iobt), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its t-win® platform, today announced that faiÇal miyara, ph.d., has been appointed as the company's chief business officer.
2024-03-06 16:11:00 - Press Release
Io Biotech Announces Acceptance Of Abstract To Be Presented At The 2024 American Association For Cancer Research (aacr) Annual Meeting
New nonclinical data strengthen evidence of individual contribution of io102 and io103 in controlling tumor growth new york, march 06, 2024 (globe newswire) -- io biotech (nasdaq: iobt), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its t-win® platform, today announced that an abstract has been accepted for presentation at the american association for cancer research annual meeting 2024 (aacr 2024), taking place april 5-10, 2024 in san diego, ca. the poster will include nonclinical data related to io biotech's lead therapeutic cancer vaccine candidate, io102-io103, currently being evaluated in a pivotal phase 3 study.
2024-03-05 16:40:00 - Press Release
Io Biotech Announces 2023 Fourth-quarter And Year-end Results
Completed enrollment of pivotal phase 3 trial of lead investigational therapeutic cancer vaccine, io102-io103, in combination with keytruda® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (orr) expected in third quarter of 2024 by independent data monitoring committee progressed clinical development of io102-io103 with first patient dosed in phase 2 basket trial of io102-io103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025 new york, march 05, 2024 (globe newswire) -- io biotech (nasdaq: iobt), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its t-win® platform, today reported financial results for the fourth quarter and year-ended december 31, 2023...
Latest News
2024-02-26 16:05:00 - GlobeNewsWire
IO Biotech to Present at 44th Annual Cowen Health Care Conference
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company's CFO, will be participating in one-on-one investor meetings at the 44th Annual Cowen Health Care Conference to be held March 4-6, 2024 in Boston, MA.
2024-02-18 11:20:54 - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
2024-01-03 03:04:32 - Seeking Alpha
IO Biotech: A Phase 3 Company Getting No Respect
IO Biotech is an immunotherapy biotech in phase 3 trials. Past failures of IDO as a target cast a pall on their potential data readouts. Nevertheless, the cheap stock price and upcoming catalysts make this an interesting play.
2023-11-08 16:30:00 - GlobeNewsWire
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare ConferenceLocation: LondonOne-on-one meetings: Wednesday, November 15, 2023Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO Event: Piper Sandler 35th Healthcare ConferenceLocation: New York, New YorkFireside chat: Wednesday, November 29, 2023 at 4:30 pm ETPresenter: Mai-Britt Zocca, PhD, President & CEOWebcast link: https://event.webcasts.com/starthere.jsp?ei=1643140&tp_key=1d3631cba2 A webcast replay of the presentations will be available on IO Biotech's website at www...
2023-09-06 08:35:00 - GlobeNewsWire
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences:
2023-06-15 09:32:10 - Zacks Investment Research
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.
2023-05-30 16:35:00 - GlobeNewsWire
IO Biotech to Present at the Jefferies Healthcare Conference
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, and Amy Sullivan, the company's CFO, will be presenting and participating in one-on-one investor meetings at the Jefferies Healthcare Conference to be held June 7-9 in New York City.
2023-02-22 07:00:00 - GlobeNewsWire
IO Biotech to Participate in March 2023 Investor Conferences
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine platform, today announced participation in two upcoming investor conferences. Mai-Britt Zocca, Ph.D., the company's President and CEO, will participate in the Novel IO Panel at the Cowen 43rd Annual Health Care Conference, taking place March 6 – 8, 2023 in Boston, MA and will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference, taking place virtually March 13 – 15, 2023. Dr. Zocca and Amy Sullivan, the company's CFO, will be available for one-on-one investor meetings during both conferences.
2022-03-04 08:00:00 - GlobeNewsWire
IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to be held virtually March 7 – 9, 2022. At the conference, IO Biotech CEO Dr. Mai-Britt Zocca will participate in the Novel IO Panel Discussion.
2021-12-03 10:55:51 - Pulse2
IO Biotech (IOBT) Stock: $21 Price Target From Morgan Stanley
The shares of IO Biotech Inc (NASDAQ: IOBT) have received a $21 price target from Morgan Stanley. These are the details.